Published in
American Society of Hematology, Blood, Supplement 1(140), p. 319-321, 2022
DOI: 10.1182/blood-2022-158465
Taylor and Francis Group, Leukemia & Lymphoma, 2(64), p. 454-461, 2022
DOI: 10.1080/10428194.2022.2140288
Links
Tools
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
Journal article published in 2022 by
Jan Philipp Bewersdorf 
,
Kishan K. Patel,
George Goshua ,
Rory Michael Shallis ,
Nikolai A. Podoltsev,
Maximilian F. Stahl,
Jessica M. Stempel,
Eytan M. Stein,
Scott F. Huntington,
Amer M. Zeidan
,
Kishan K. Patel,
George Goshua ,
Rory Michael Shallis ,
Nikolai A. Podoltsev,
Maximilian F. Stahl,
Jessica M. Stempel,
Eytan M. Stein,
Scott F. Huntington,
Amer M. Zeidan
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 